Theravance Biopharma (Theravance Biopharma) Cash And Cash Equivalents : $39.55 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Cash And Cash Equivalents?

Theravance Biopharma's quarterly cash and cash equivalents declined from Jun. 2023 ($105.60 Mil) to Sep. 2023 ($71.69 Mil) but then stayed the same from Sep. 2023 ($71.69 Mil) to Dec. 2023 ($39.55 Mil).

Theravance Biopharma's annual cash and cash equivalents increased from Dec. 2021 ($89.96 Mil) to Dec. 2022 ($298.17 Mil) but then declined from Dec. 2022 ($298.17 Mil) to Dec. 2023 ($39.55 Mil).

Theravance Biopharma Cash And Cash Equivalents Historical Data

The historical data trend for Theravance Biopharma's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Cash And Cash Equivalents Chart

Theravance Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

58.06

81.47

89.96

298.17

39.55

Theravance Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															187.67	105.60	71.69	39.55	-

Theravance Biopharma Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Theravance Biopharma (NAS:TBPH) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Theravance Biopharma Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma (Theravance Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (NAS:TBPH) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

0TB:Germany

Address

Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104

Website

https://www.theravance.com

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Executives

Rhonda Farnum	officer: SVP, Comm & Medical Affairs	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Richard A Graham	officer: SVP, Development	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kelly James Connor	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Brett A. Grimaud	officer: SVP, Gen Counsel and Secretary	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Aziz Sawaf	officer: SVP & Chief Financial Officer	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Rick E Winningham	director, officer: Chief Executive Officer	901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Andrew A. Hindman	officer: SVP, Chief Financial Officer	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Eli Samaha	10 percent owner	ONE WORLD TRADE CENTER, FLOOR 65, NEW YORK NY 10007
Wam Gp Llc	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Weiss Asset Management Lp	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Philip D Worboys	officer: SVP, Translational Science	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Brett K Haumann	officer: VP-Clinical Develop.	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402